Anove LogoAnove LogoExplAIn
MapsAI frontrunners
Back to Directory

ChestLink

by Oxipit

AI Application
Low Confidence

ChestLink is software for chest X-rays, used in radiology departments, including for primary-care referrals. The vendor says it identifies chest X-rays with no abnormalities and, for studies where it is highly confident the image is normal, writes the final report on its own, without a radiologist; if there is the slightest suspicion of an abnormality it leaves the study to the radiologist. The notified-body certificate scope describes it as standalone computer-assisted diagnostic software for chest X-ray analysis and reporting. The vendor recommends a staged roll-out: a retrospective analysis on the site's own images, then a supervised period in which ChestLink writes preliminary reports that staff and Oxipit monitor through a dashboard, and only then autonomous reporting, with reporting data kept in the dashboard for traceability. It is part of Oxipit's CXR Suite alongside ChestEye and Quality. The vendor does not say where images are processed or hosted. Oxipit has been part of Sectra since 2026.

Visit Website

Transparency Score

Weighted across four pillars · updated October 20, 2026

Overall grade
33% weighted
ABCDF
Model
—
Not yet assessed
Infrastructure
—
Not yet assessed

Capabilities

Normal Chest Xray Identification
Autonomous Normal Reporting
Worklist Triage
Preliminary Reporting

Vendor Information

Complete information about the vendor/provider of this AI application

OxipitView all products →
Sectra Lithuania, UAB(Trading as: Oxipit (part of Sectra))
Contact Information
oxipit.ai
info@oxipit.ai
Registered Address
Saulėtekio al. 15-1, Vilnius, Vilnius County, LT-10224, LT

EU AI Act Provider Information

Verification Status:
Unverified
(Last verified: October 20, 2026)
Sectra Lithuania, UAB(Trading as: Oxipit (part of Sectra))
Saulėtekio al. 15-1, Vilnius, Vilnius County, LT-10224, LT
info@oxipit.ai
Compliance Documents
CE Marking: Certified
Notified Body: TÜV Rheinland LGA Products GmbH(Cert: HZ 1550682-1)
Oxipit says ChestLink reports autonomously only on studies where it is highly confident there are no abnormalities, leaves any study with 'the slightest suspicion' to the radiologist, and recommends retrospective analysis and supervised operation before autonomous reporting (https://oxipit.ai/article/autonomous-ai-medical-imaging-understanding-chestlink/, 5 Apr 2022, read 2026-10-20). In the Finnish primary-care study it cites, ChestLink identified 36.4% of studies without significant findings at 99.8% sensitivity, with nine false negatives (slightly enlarged heart, slightly increased opacification, a small pleural effusion) among 9,579 cases (https://oxipit.ai/products/chestlink/, read 2026-10-20). The vendor refers users to the user guide for indications, contraindications and warnings; it is not public (https://oxipit.ai/regulatory-compliance-and-certifications/, read 2026-10-20).
Compliance & Risk

Get insights into risk by running assessments on this AI application.

Work at Oxipit? Claim this listing to correct or complete the data.

Added: October 20, 2026
Updated: October 20, 2026

Ready to manage AI applications?

Track, assess, and govern your AI applications with Anove.

Anove LogoAnove LogoAnove International B.V.

Helping organizations discover and manage AI applications responsibly. Your trusted source for AI governance and compliance.

Quick Links

  • Browse Directory
  • FAQ
  • AI maps by industry
  • Sign In

Resources

  • Documentation
  • Status
  • Anove.ai

Terms

  • Privacy Policy
  • Terms & Conditions
  • Responsible Disclosure
  • AI Legal Notice
  • Security Policy

© 2026 Anove International B.V. All rights reserved.